Sage Therapeutics Starting Phase 2 Study of SAGE-547 (6-hour infusion drug) for Treating Tinnitus - Tinnitus Treatment Report
Sage Therapeutics slumps, Biogen bounces
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected
Sage Therapeutics CEO: Mental health is integral to returning to work
Sage Therapeutics
Did SAGE Therapeutics Just Break the CNS Curse? | BioSpace
Sage Therapeutics Shares Plummet on Subpar Depression-Treatment Study Results - WSJ
FDA approval for zuranolone offers hope in postpartum depression
Sage Therapeutics (@SageBiotech) / X
Layoffs as Sage Therapeutics reshuffles CNS pipeline
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage rethinks SAGE-217 program after phase 3 failure | Fierce Biotech
Rx Product News: April 2023
Sage Therapeutics wins priority review for intravenous postpartum depression drug - MassDevice
Sage Therapeutics stock falls after stock offering, Q3 miss | Seeking Alpha
Biotech layoffs 2023: Sage Therapeutics cuts nearly half its staff in wake of partial FDA rejection - Boston Business Journal
Sage Therapeutics Archives - DelveInsight
Sage Therapeutics fires 40% of staff after FDA rejected MDD bid - Pharmaceutical Technology
Sage Therapeutics plunges after FDA decision on depression drug
Why Is Sage Therapeutics (SAGE) Stock Down 48% Today? | InvestorPlace
Sage Stock: FDA Documents Suggest Its Battle In Depression Will Be Trickier Than Expected | Investor's Business Daily
Sage Therapeutics - Timberline Construction
Oppenheimer cuts Sage Therapeutics to perform, cites FDA setback (NASDAQ: SAGE) | Seeking Alpha
Sage Therapeutics' SAGE-718 granted Orphan Drug Designation by European Medicines Agency for Huntington's Disease treatment - Pharma Journalist
Sage tumbles to record low on clinical depression pill setback | Reuters
Goldman Sachs Maintains Sage Therapeutics (SAGE) Neutral Recommendation
/cloudfront-us-east-2.images.arcpublishing.com/reuters/IXYUV47KYRP5DGR3BXFFW4NLJE.jpg "Sage Therapeutics to cut about 188 jobs after depression drug setback | Reuters")